Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Valspar Q1 Profit Down, Cuts FY View; Shares Down

RELATED NEWS
Trade VAL now with 

Paints and coatings maker Valspar Corp. (VAL: Quote), Tuesday reported a slight decline in profit for the first quarter, as revenues dropped due to weaker-than-anticipated international markets. Both earnings and revenues for the quarter fell short of analysts' estimates.

Moving ahead, the company trimmed its full-year earnings expectations, anticipating weak demand in certain international markets to continue. Valspar shares are currently down near nine percent on the New York Stock Exchange.

Chief Executive Gary Hendrickson said, "Although we made substantial progress this quarter on a number of key initiatives, international markets were weaker than anticipated."

The Minneapolis, Minnesota-based company's first-quarter profit inched down to $55.02 million from $55.78 million last year. On a per share basis, earnings improved to $0.60 from $0.58 last year, on lower number of shares outstanding for the quarter.

Last year, the company recorded a one-time restructuring charge of $0.04 per share. The absence of any charges in the latest first-quarter partially helped the company's bottom line.

On average, 13 analysts polled by Thomson Reuters estimated earnings of $0.67 per share for the quarter. Analysts' expectations typically exclude one-time items.

First-quarter revenues dropped to $875.2 million from $885.6 million last year. Analysts estimated revenues of $922.05 million for the quarter.

On a reported basis, gross margin advanced to 33.6 percent from 33.1 percent last year.

Looking forward to full-year 2013, Valspar now expect earnings of $3.60 to $3.80 per share, down from previous estimate of $3.65 and $3.85 per share. The Street currently expect earnings of $3.79 per share for the year.

VAL is currently trading at $61.00, down $5.93 or 8.86%, on a volume of 1.3 million, which is above the three-month average.

Register
To receive FREE breaking news email alerts for The Valspar Corp and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.